Healthcare provider profile · identity verified

Cesar A Carranza, MD

Family Practice · CHICAGO, IL · NPI 1447207022

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	358	101
Levothyroxine Sodium	Levothyroxine Sodium	238	79
Amlodipine Besylate	Amlodipine Besylate	200	51
Metformin Hcl	Metformin Hcl	174	53
Diclofenac Sodium	Diclofenac Sodium	150	36
Furosemide	Furosemide	134	45
Metoprolol Succinate	Metoprolol Succinate	131	38
Lisinopril	Lisinopril	128	37
Pantoprazole Sodium	Pantoprazole Sodium	128	42
Gabapentin	Gabapentin	123	34
Omeprazole	Omeprazole	119	35
Tradjenta	Linagliptin	112	30
Albuterol Sulfate Hfa	Albuterol Sulfate	91	33
Donepezil Hcl	Donepezil Hcl	88	28
Losartan Potassium	Losartan Potassium	82	27
Sertraline Hcl	Sertraline Hcl	78	18
Carvedilol	Carvedilol	68	21
Ezetimibe	Ezetimibe	68	17
Rosuvastatin Calcium	Rosuvastatin Calcium	68	21
Famotidine	Famotidine	64	18
Jardiance	Empagliflozin	64	16
Montelukast Sodium	Montelukast Sodium	62	14
Enalapril Maleate	Enalapril Maleate	59	13
Fluticasone Propionate	Fluticasone Propionate	58	27
Januvia	Sitagliptin Phosphate	55	suppressed
Mirtazapine	Mirtazapine	55	19
Potassium Chloride	Potassium Chloride	55	19
Ibuprofen	Ibuprofen	52	20
Meloxicam	Meloxicam	51	17
Tamsulosin Hcl	Tamsulosin Hcl	51	15
Meclizine Hcl	Meclizine Hcl	45	15
Baclofen	Baclofen	42	suppressed
Metformin Hcl Er	Metformin Hcl	42	14
Hydralazine Hcl	Hydralazine Hcl	41	11
Alprazolam	Alprazolam	40	12
Azithromycin	Azithromycin	40	32
Betamethasone Dipropionate	Betamethasone Dipropionate	39	suppressed
Eliquis	Apixaban	39	12
Valsartan	Valsartan	39	11
Myrbetriq	Mirabegron	37	suppressed
Glipizide Er	Glipizide	36	suppressed
Alendronate Sodium	Alendronate Sodium	35	14
Clopidogrel	Clopidogrel Bisulfate	35	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Allopurinol	Allopurinol	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Memantine Hcl	Memantine Hcl	31	11
Mupirocin	Mupirocin	31	suppressed
Simvastatin	Simvastatin	31	13
Levofloxacin	Levofloxacin	30	25
Vascepa	Icosapent Ethyl	30	12
Hydrochlorothiazide	Hydrochlorothiazide	29	13
Hydrocortisone	Hydrocortisone	29	11
Glipizide	Glipizide	28	11
Lorazepam	Lorazepam	28	suppressed
Nystatin	Nystatin	28	11
Pioglitazone Hcl	Pioglitazone Hcl	28	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	27	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Linzess	Linaclotide	27	suppressed
Ozempic	Semaglutide	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Glimepiride	Glimepiride	24	suppressed
Terbinafine Hcl	Terbinafine Hcl	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Naproxen	Naproxen	23	12
Clonidine Hcl	Clonidine Hcl	22	suppressed
Lansoprazole	Lansoprazole	22	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	17
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Megestrol Acetate	Megestrol Acetate	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Sucralfate	Sucralfate	17	suppressed
Trazodone Hcl	Trazodone Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Ammonium Lactate	Ammonium Lactate	16	suppressed
Fenofibrate	Fenofibrate,micronized	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	15	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Cephalexin	Cephalexin	14	14
Cilostazol	Cilostazol	14	suppressed
Clonazepam	Clonazepam	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Amoxicillin	Amoxicillin	13	12
Ondansetron Odt	Ondansetron	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Prednisone	Prednisone	13	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Mupirocin	Mupirocin Calcium	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Atrovent Hfa	Ipratropium Bromide	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error